EQA 2002 WHO/CDC/IACMAC External Quality Assurance Program
In 2002 IACMAC continued EQA IACMAC program.
The latter phase of EQA IACMAC was performed in collaboration with European antimicrobial resistance surveillance system (EARSS). Strains were rendered by Paster Institute (France) and were prepared by National External Quality Assurance System of the United Kingdom (UK NEQAS).
45 microbiological laboratories of Russian Federation in Arkhangelsk, Vladivostok, Volgograd, Voronezh, Ekaterinburg, Irkutsk, Kazan, Krasnoyarsk, Lipetsk, Moscow, Nizhni Novgorod, Chelny, Novosibirsk, Omsk, Perm, Ryazan, Saint Petersburg, Smolensk, Stavropol, Tolyatti, Tomsk, Ufa, Chelyabinsk, Yaroslavl participated in the project.
In 2002 IACMAC EQA program included identification and determination of antibiotic susceptibility to five control strains: 1) U2A 1556 S.aureus (MRSA), 2) U2A 1557 E.coli (susceptible isolate), 3) U2A 1526 E.coli (β-lactamase producing strain, CTX-M, resistant to aminoglycosides and fluoroquinolones), 4) U2A 1580 S.pneumoniae (penicillin resistant pneumococcus, MLS-R) and 5) U2A 805 E.faecium (VRE with high level of resistance to gentamicin).
Purpose of the phase
Particular attention was paid to determination of susceptibility to antimicrobial agents and estimation of ability of a laboratory to reveal clinically significant resistance mechanisms (resistance to meticillin in staphylococcus, production of β-lactamases in enterobacteria, resistance to penicillin in pneumococcus, and resistance to vancomicin and to aminoglycosideds in entorococci).
Analyzing the results
The organizers of EQA suppose that the results of this step in EQA program are of a considerable value and are useful in improving working quality of laboratories. With the framework of IACMAC conference «Surgical infections: Prevention and management» held on 29-30, May in Moscow, organizers of the project discussed mistakes with participants who were then presented with certificates of participation in EQA IACMAC program.
In autumn 2003 the results of this EQA IACMAC will be published in the journal «Clinical Microbiology and Antimicrobial Chemotherapy»